基于证据的指导方针,用于偏头痛的药理治疗
Raffaele Ornello1, Valeria Caponnetto2, Fayyaz Ahmed3
1Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Cephalalgia : an international journal of headache
|April 25, 2025
概括
这些基于证据的指导方针为药理性偏头痛治疗提供了明确的建议,整合了研究和专家意见,以改善患者的护理. 它们强调了需要进一步研究的领域,以实现最佳的头痛管理.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 偏头痛是一种常见的神经疾病,需要标准化的治疗方法.
- 现有的治疗方案受益于基于证据的指导方针,以确保最佳的患者结果.
研究的目的:
- 为偏头痛的药理治疗提出基于证据的指导方针.
- 为管理偏头痛患者的医疗保健专业人员提供明确,可行的建议.
主要方法:
- 在多个数据库中进行系统的文献审查,遵循Cochrane审查方法.
- 结合随机对照试验和专家意见的证据.
- 使用推,评估,开发和评估 (GRADE) 方法进行证据质量评估.
主要成果:
- 制定了药物治疗偏头痛的综合指南.
- 确定了当前研究的差距,包括缺乏对药物进行对比和长期结果研究.
结论:
- 这些指南为标准化偏头痛治疗提供了坚实的基础.
- 在不同的医疗保健机构中促进高质量的偏头痛护理.
- 强调需要进一步的研究来完善治疗策略.
相关概念视频
Management of Insomnia
185
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
185
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Antidepressant Drugs: MAOIs and Other Agents
160
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
160
Drug Therapy
28
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
28
Analgesia and Pain Management
397
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
397
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
91
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
91


